Last reviewed · How we verify
NCT04756674
The Impact of Covid-19 on Skeletal Muscle
trial testing No intervetion will be used in Covid19. Withdrawn.
1 October 2022
Quick facts
| Lead sponsor | University of Nottingham |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 10 March 2021 |
| Primary completion | 1 October 2022 |
| Estimated completion | 1 October 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- No intervetion will be used
Conditions studied
- Covid19 — all drugs for Covid19 →
- Muscle Loss — all drugs for Muscle Loss →
- Mitochondrial Alteration — all drugs for Mitochondrial Alteration →
Sponsor
University of Nottingham
Who can join
40 and older, any sex, with Covid19 or Muscle Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the recent worldwide outbreak of the COVID-19 infection and the huge impact it has had upon lives in the UK, it is key to increase knowledge on the impact of the virus on the body. Certain aspects of the virus' characteristics are also poorly understood: The reason behind the variation in response between individuals, and the long-term impacts of infection upon the body. It is already known from previous research that muscle-health plays an important role in health, with other illnesses known to have an impact upon muscle health. A large number of studies have investigated the relationship between muscle and health, with an increasing focus upon the impact upon the mitochondria within the muscle cells. Mitochondria are the energy-producing component of a cell and are vital not just for the muscle-cells but for the body as a whole. The researchers hope that by investigating the impact of COVID-19 infection upon human skeletal muscle, the question of why individuals have different responses to the infection and the mechanism of the longer-term impact of infection can be answered. This added knowledge will then, hopefully, be able to guide therapy targets in the future.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04756674
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other University of Nottingham trials
Trials by the same sponsor.
- NCT07518381 — Medication Understanding in MS · not yet recruiting
- NCT07355556 — Technology Supported Improvement, Management and Prevention of Accidental Falls in Hospitals · not yet recruiting
- NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
- NCT07237529 — What is the Feasibility of Narrative Exposure Therapy (NET) for People Experiencing Psychosis? · NA · not yet recruiting
- NCT07237997 — Protein Supplementation During Dialysis (PROSED) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04756674 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Nottingham
- Last refreshed: 2 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04756674.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing